Cabergoline versus levodopa monotherapy: A decision analysis
Identifieur interne : 001801 ( Main/Exploration ); précédent : 001800; suivant : 001802Cabergoline versus levodopa monotherapy: A decision analysis
Auteurs : Antje M. Smala [Allemagne] ; E. Annika Spottke [Allemagne] ; Olaf Machat [Allemagne] ; Uwe Siebert [États-Unis] ; Dieter Meyer [Allemagne] ; Rudolf Köhne-Volland [Allemagne] ; Martin Reuther [Allemagne] ; Janeen Duchane [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; Karin B. Berger [Allemagne] ; Richard C. Dodel [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-08.
English descriptors
- KwdEn :
Abstract
We evaluated the incremental cost‐effectiveness of cabergoline compared with levodopa monotherapy in patients with early Parkinson's disease (PD) in the German healthcare system. The study design was based on cost‐effectiveness analysis using a Markov model with a 10‐year time horizon. Model input data was based on a clinical trial “Early Treatment of PD with Cabergoline” as well as on cost data of a German hospital/office‐based PD network. Direct and indirect medical and nonmedical costs were included. Outcomes were costs, disease stage, cumulative complication incidence, and mortality. An annual discount rate of 5% was applied and the societal perspective was chosen. The target population included patients in Hoehn and Yahr Stages I to III. It was found that the occurrence of motor complications was significantly lower in patients on cabergoline monotherapy. For patients aged ≥60 years of age, cabergoline monotherapy was cost effective when considering costs per decreased UPDRS score. Each point decrease in the UPDRS (I‐IV) resulted in costs of €1,031. Incremental costs per additional motor complication‐free patient were €104,400 for patients <60 years of age and €57,900 for patients ≥60 years of age. In conclusion, this decision‐analytic model calculation for PD was based almost entirely on clinical and observed data with a limited number of assumptions. Although costs were higher in patients on cabergoline, the corresponding cost‐effectiveness ratio for cabergoline was at least as favourable as the ratios for many commonly accepted therapies. © 20032003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10465
Affiliations:
- Allemagne, États-Unis
- Bavière, District de Giessen, District de Haute-Bavière, Hesse (Land), Massachusetts, Michigan
- Marbourg, Munich
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cabergoline versus levodopa monotherapy: A decision analysis</title><author><name sortKey="Smala, Antje M" sort="Smala, Antje M" uniqKey="Smala A" first="Antje M." last="Smala">Antje M. Smala</name></author><author><name sortKey="Spottke, E Annika" sort="Spottke, E Annika" uniqKey="Spottke E" first="E. Annika" last="Spottke">E. Annika Spottke</name></author><author><name sortKey="Machat, Olaf" sort="Machat, Olaf" uniqKey="Machat O" first="Olaf" last="Machat">Olaf Machat</name></author><author><name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name></author><author><name sortKey="Meyer, Dieter" sort="Meyer, Dieter" uniqKey="Meyer D" first="Dieter" last="Meyer">Dieter Meyer</name></author><author><name sortKey="Kohne Olland, Rudolf" sort="Kohne Olland, Rudolf" uniqKey="Kohne Olland R" first="Rudolf" last="Köhne-Volland">Rudolf Köhne-Volland</name></author><author><name sortKey="Reuther, Martin" sort="Reuther, Martin" uniqKey="Reuther M" first="Martin" last="Reuther">Martin Reuther</name></author><author><name sortKey="Duchane, Janeen" sort="Duchane, Janeen" uniqKey="Duchane J" first="Janeen" last="Duchane">Janeen Duchane</name></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name></author><author><name sortKey="Berger, Karin B" sort="Berger, Karin B" uniqKey="Berger K" first="Karin B." last="Berger">Karin B. Berger</name></author><author><name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C." last="Dodel">Richard C. Dodel</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:68EE7EDE4F4916AF2D0FD7B4DAEA24F1CD5DAF23</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10465</idno><idno type="url">https://api.istex.fr/document/68EE7EDE4F4916AF2D0FD7B4DAEA24F1CD5DAF23/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000960</idno><idno type="wicri:Area/Main/Curation">000836</idno><idno type="wicri:Area/Main/Exploration">001801</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cabergoline versus levodopa monotherapy: A decision analysis</title><author><name sortKey="Smala, Antje M" sort="Smala, Antje M" uniqKey="Smala A" first="Antje M." last="Smala">Antje M. Smala</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medical Economics Research Group (MERG), Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Spottke, E Annika" sort="Spottke, E Annika" uniqKey="Spottke E" first="E. Annika" last="Spottke">E. Annika Spottke</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Bonn</wicri:regionArea><wicri:noRegion>University of Bonn</wicri:noRegion><wicri:noRegion>University of Bonn</wicri:noRegion></affiliation></author><author><name sortKey="Machat, Olaf" sort="Machat, Olaf" uniqKey="Machat O" first="Olaf" last="Machat">Olaf Machat</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Metronomia, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Center for Risk Analysis, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Meyer, Dieter" sort="Meyer, Dieter" uniqKey="Meyer D" first="Dieter" last="Meyer">Dieter Meyer</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Metronomia, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Kohne Olland, Rudolf" sort="Kohne Olland, Rudolf" uniqKey="Kohne Olland R" first="Rudolf" last="Köhne-Volland">Rudolf Köhne-Volland</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Metronomia, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Reuther, Martin" sort="Reuther, Martin" uniqKey="Reuther M" first="Martin" last="Reuther">Martin Reuther</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Duchane, Janeen" sort="Duchane, Janeen" uniqKey="Duchane J" first="Janeen" last="Duchane">Janeen Duchane</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pharmacia‐Upjohn, Kalamazoo, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Berger, Karin B" sort="Berger, Karin B" uniqKey="Berger K" first="Karin B." last="Berger">Karin B. Berger</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Medical Economics Research Group (MERG), Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C." last="Dodel">Richard C. Dodel</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Bonn</wicri:regionArea><wicri:noRegion>University of Bonn</wicri:noRegion><wicri:noRegion>University of Bonn</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-08">2003-08</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="898">898</biblScope><biblScope unit="page" to="905">905</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">68EE7EDE4F4916AF2D0FD7B4DAEA24F1CD5DAF23</idno><idno type="DOI">10.1002/mds.10465</idno><idno type="ArticleID">MDS10465</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Markov</term><term>Parkinson's disease</term><term>cabergoline</term><term>cost</term><term>decision analysis</term><term>levodopa</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated the incremental cost‐effectiveness of cabergoline compared with levodopa monotherapy in patients with early Parkinson's disease (PD) in the German healthcare system. The study design was based on cost‐effectiveness analysis using a Markov model with a 10‐year time horizon. Model input data was based on a clinical trial “Early Treatment of PD with Cabergoline” as well as on cost data of a German hospital/office‐based PD network. Direct and indirect medical and nonmedical costs were included. Outcomes were costs, disease stage, cumulative complication incidence, and mortality. An annual discount rate of 5% was applied and the societal perspective was chosen. The target population included patients in Hoehn and Yahr Stages I to III. It was found that the occurrence of motor complications was significantly lower in patients on cabergoline monotherapy. For patients aged ≥60 years of age, cabergoline monotherapy was cost effective when considering costs per decreased UPDRS score. Each point decrease in the UPDRS (I‐IV) resulted in costs of €1,031. Incremental costs per additional motor complication‐free patient were €104,400 for patients <60 years of age and €57,900 for patients ≥60 years of age. In conclusion, this decision‐analytic model calculation for PD was based almost entirely on clinical and observed data with a limited number of assumptions. Although costs were higher in patients on cabergoline, the corresponding cost‐effectiveness ratio for cabergoline was at least as favourable as the ratios for many commonly accepted therapies. © 20032003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>États-Unis</li></country><region><li>Bavière</li><li>District de Giessen</li><li>District de Haute-Bavière</li><li>Hesse (Land)</li><li>Massachusetts</li><li>Michigan</li></region><settlement><li>Marbourg</li><li>Munich</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Smala, Antje M" sort="Smala, Antje M" uniqKey="Smala A" first="Antje M." last="Smala">Antje M. Smala</name></region><name sortKey="Berger, Karin B" sort="Berger, Karin B" uniqKey="Berger K" first="Karin B." last="Berger">Karin B. Berger</name><name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C." last="Dodel">Richard C. Dodel</name><name sortKey="Dodel, Richard C" sort="Dodel, Richard C" uniqKey="Dodel R" first="Richard C." last="Dodel">Richard C. Dodel</name><name sortKey="Kohne Olland, Rudolf" sort="Kohne Olland, Rudolf" uniqKey="Kohne Olland R" first="Rudolf" last="Köhne-Volland">Rudolf Köhne-Volland</name><name sortKey="Machat, Olaf" sort="Machat, Olaf" uniqKey="Machat O" first="Olaf" last="Machat">Olaf Machat</name><name sortKey="Meyer, Dieter" sort="Meyer, Dieter" uniqKey="Meyer D" first="Dieter" last="Meyer">Dieter Meyer</name><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><name sortKey="Reuther, Martin" sort="Reuther, Martin" uniqKey="Reuther M" first="Martin" last="Reuther">Martin Reuther</name><name sortKey="Spottke, E Annika" sort="Spottke, E Annika" uniqKey="Spottke E" first="E. Annika" last="Spottke">E. Annika Spottke</name><name sortKey="Spottke, E Annika" sort="Spottke, E Annika" uniqKey="Spottke E" first="E. Annika" last="Spottke">E. Annika Spottke</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Siebert, Uwe" sort="Siebert, Uwe" uniqKey="Siebert U" first="Uwe" last="Siebert">Uwe Siebert</name></region><name sortKey="Duchane, Janeen" sort="Duchane, Janeen" uniqKey="Duchane J" first="Janeen" last="Duchane">Janeen Duchane</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001801 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001801 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:68EE7EDE4F4916AF2D0FD7B4DAEA24F1CD5DAF23
|texte= Cabergoline versus levodopa monotherapy: A decision analysis
}}
| This area was generated with Dilib version V0.6.23. |  |